Silymarin's anti-cancer activity has been reported in multiple types of cancers such as lung cancer, breast cancer, colon cancer, and prostate cancer. It has been observed that silymarin is able to inhibit cancer cell proliferation and invasion by inducing cell cycle arrest and apoptosis. One of the most promising aspects of silymarin is its ability to enhance the efficacy of chemotherapy and radiation therapy. A study conducted on human lung cancer cells showed that silymarin in combination with cisplatin resulted in a higher inhibition of cancer cell proliferation and increased apoptosis. Similarly, another study conducted on breast cancer cells showed that the combination of silymarin and tamoxifen (a drug used in breast cancer treatment) resulted in a synergistic effect in inhibiting cancer cell growth. Another important feature of silymarin is its ability to reduce the side effects of chemotherapy and radiation therapy. A study conducted on breast cancer patients showe...
The article "Silymarin: A Promising Molecule for Cancer Therapy" published in the journal Molecules in 2020 reviews the potential of silymarin, a flavonoid isolated from milk thistle, as a promising anti-cancer agent. The authors report that silymarin has shown significant anti-cancer properties against various types of cancer, including breast, prostate, lung, liver, colorectal, and skin cancers. Silymarin has been shown to induce apoptosis, inhibit angiogenesis, and suppress cell proliferation, invasion, and metastasis of cancer cells. The article summarizes several in vitro and in vivo studies that demonstrate the potential of silymarin to inhibit tumor growth and enhance the effectiveness of chemotherapy and radiotherapy. The authors suggest that silymarin has the potential to overcome drug resistance in cancer cells, making it a promising molecule for cancer therapy. Article click here Silymarin has also been found to have minimal toxicity and is well-tolerated by patie...